A5079986597- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Vascular Tumors and Angiosarcomas
- Bone Tumor Diagnosis and Treatments
- Hormonal and reproductive studies
- Cardiac tumors and thrombi
- Erythropoietin and Anemia Treatment
- Colorectal and Anal Carcinomas
- Melanoma and MAPK Pathways
- Colorectal Cancer Surgical Treatments
- Statistical Methods in Clinical Trials
- Tumors and Oncological Cases
- Blood transfusion and management
- Endometrial and Cervical Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Neuroblastoma Research and Treatments
- Obstructive Sleep Apnea Research
- Renal cell carcinoma treatment
- Glutathione Transferases and Polymorphisms
- Effects of Radiation Exposure
- Brain Metastases and Treatment
- Soft tissue tumors and treatment
- Urologic and reproductive health conditions
Hospital General Universitario Gregorio Marañón
2014-2024
Hospital Universitario Araba
2024
Hospital Universitario Puerta del Mar
2021
The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the BCR using different analytic methods.Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed Prentice criteria (including landmark analyses) two-stage meta-analytic approach (estimating Kendall's tau R2)....
Abstract Anaemia is defined by the presence of haemoglobin (Hb) levels < 13 g/dL in men and 12 women. Up to 39% cancer patients present it at time diagnosis up 40% have iron deficiency. causes fatigue, functional deterioration a reduction quality life; has also been associated with poorer response anti-tumour treatment lower survival. Basic diagnostic tests for anaemia are simple should be routine part clinical practice. These guidelines review available evidence on use different...
Abstract Background Encorafenib plus binimetinib (EB) is a standard-of-care treatment for advanced BRAFV600-mutant melanoma. We assessed the efficacy and safety of encorafenib in patients with melanoma brain metastasis (BM) explored if radiotherapy improves duration response. Methods E-BRAIN/GEM1802 was prospective, multicenter, single-arm, phase II trial that enrolled BM. Patients received 450 mg once daily 45 BID, those who achieved partial response or stable disease at first tumor...
Background Salvage radiotherapy (SRT) and androgen‐deprivation therapy (ADT) are widely used in routine clinical practice to treat patients with prostate cancer who develop biochemical recurrence (BCR) after radical prostatectomy (RP). However, there is no standard‐of‐care consensus on optimal duration ADT. Investigators propose three distinct risk groups treated SRT order better define the indications of ADT combined SRT. Study design The URONCOR 06‐24 trial (ClinicalTrials.gov identifier...
The optimal prognostic value of testosterone following androgen deprivation therapy (ADT) is controversial. We studied the effect serum levels on clinical outcome in localized prostate cancer (PCa) treated with ADT and high-dose radiotherapy (HRT).The DART01/05 trial randomized 355 men intermediate high-risk PCa to 4 months plus HRT (STADT, N = 178) or same treatment followed by 24 (LTADT, 177). This study included patients LTADT who had at least 3 determinations during (N 154). Patients...
4580 Background: Hormone therapy plus radiotherapy significantly decreases recurrences and mortality of patients affected by locally advanced prostate cancer (PCa). Controversy remains about the optimal duration androgen deprivation (AD) when associated to high-dose (HDRT). This trial was designed determine whether long-term AD (LTAD) is superior short-term (STAD) in setting HDRT Methods: Eligibility included with cT1c-T3aN0M0 adenocarcinoma intermediate high risk factors according NCCN...
Clear cell sarcoma (CCS) is a rare and aggressive soft tissue sarcoma. CCS characterized by the translocation t(12;22) (q13;q12), involving fusion of EWSR1 ATF1 genes, less frequently gene EWSR1-CREB1. Usually, CCSs are considered poorly responsive to conventional chemotherapy. However, trabectedin has shown activity against translocation-related sarcomas. Furthermore, preclinical results suggest that promising antitumor agent for CCS, potentially inducing melanocytic differentiation.We...
9546 Background: Laboratory and clinical experiences suggest that radiotherapy may be synergistic with anti-CTLA-4 strategies. This hypothesis is explored in melanoma patients (pts) brain metastases (BM) not candidate to surgery/radiosurgery. Methods: Single arm phase-2 trial evaluating Ipilimumab (IPI) whole RT (WBRT), pts unresectable BM. Endpoints: Primary: 1-year overall survival (OS@1y). Secondaries: progression free (PFS), objective response rate (ORR) safety. Main eligibility...
e15036 Background: Controversy remains about the timing and optimal duration of AD when associated to high- dose radiotherapy (HDRT). The purpose this trial is determine whether long-term (LTAD) superior short-term (STAD) in setting HDRT. Methods: Patients with cT1c-T3aN0M0 adenocarcinoma prostate intermediate high risk factors according NCCN criteria PSA less than 100 ng/ml were included. All patients received 4 months neoadjuvant concomitant + HDRT (minimum 76 Gy) before they randomized...